{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T18:46:55Z","timestamp":1790621215910,"version":"4.1.0"},"reference-count":34,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2016,12,15]],"date-time":"2016-12-15T00:00:00Z","timestamp":1481760000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JHD"],"published-print":{"date-parts":[[2016,12,15]]},"DOI":"10.3233\/jhd-160226","type":"journal-article","created":{"date-parts":[[2016,12,17]],"date-time":"2016-12-17T00:41:30Z","timestamp":1481935290000},"page":"347-355","source":"Crossref","is-referenced-by-count":35,"title":["LBH589, A Hydroxamic Acid-Derived HDAC Inhibitor, is Neuroprotective in Mouse Models of Huntington\u2019s Disease"],"prefix":"10.1177","volume":"5","author":[{"given":"Vanita","family":"Chopra","sequence":"first","affiliation":[{"name":"Department of Neurology, Harvard Medical School, Massachusetts General Hospital, Charlestown, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa","family":"Quinti","sequence":"additional","affiliation":[{"name":"Department of Neurology, Harvard Medical School, Massachusetts General Hospital, Charlestown, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prarthana","family":"Khanna","sequence":"additional","affiliation":[{"name":"Department of Neurology, Harvard Medical School, Massachusetts General Hospital, Charlestown, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Paganetti","sequence":"additional","affiliation":[{"name":"Novartis Institutes for Biomedical Research, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rainer","family":"Kuhn","sequence":"additional","affiliation":[{"name":"Novartis Institutes for Biomedical Research, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne B.","family":"Young","sequence":"additional","affiliation":[{"name":"Department of Neurology, Harvard Medical School, Massachusetts General Hospital, Charlestown, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksey G.","family":"Kazantsev","sequence":"additional","affiliation":[{"name":"Department of Neurology, Harvard Medical School, Massachusetts General Hospital, Charlestown, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Hersch","sequence":"additional","affiliation":[{"name":"Department of Neurology, Harvard Medical School, Massachusetts General Hospital, Charlestown, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","reference":[{"issue":"3","key":"10.3233\/JHD-160226_ref1","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1051\/jbio:2005026","article-title":"Huntington\u2019s disease: Intracellular signaling pathways and neuronal death","volume":"199","author":"Humbert","year":"2005","journal-title":"J Soc Biol"},{"issue":"3","key":"10.3233\/JHD-160226_ref2","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1152\/physrev.00041.2009","article-title":"Molecular mechanisms and potential therapeutical targets in Huntington\u2019s disease","volume":"90","author":"Zuccato","year":"2010","journal-title":"Physiol Rev"},{"issue":"9","key":"10.3233\/JHD-160226_ref3","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S0166-2236(00)01609-X","article-title":"Transcriptional dysregulation in Huntington\u2019s disease","volume":"23","author":"Cha","year":"2000","journal-title":"Trends Neurosci"},{"issue":"4","key":"10.3233\/JHD-160226_ref4","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.pneurobio.2007.02.005","article-title":"Drug targeting of dysregulated transcription in Huntington\u2019s disease","volume":"83","author":"Kazantsev","year":"2007","journal-title":"Prog Neurobiol"},{"issue":"4","key":"10.3233\/JHD-160226_ref5","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1073\/pnas.0437870100","article-title":"Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington\u2019s disease","volume":"100","author":"Hockly","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"28","key":"10.3233\/JHD-160226_ref6","doi-asserted-by":"crossref","first-page":"9418","DOI":"10.1523\/JNEUROSCI.23-28-09418.2003","article-title":"Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington\u2019s disease mice","volume":"23","author":"Ferrante","year":"2003","journal-title":"J Neurosci"},{"issue":"1","key":"10.3233\/JHD-160226_ref7","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1074\/jbc.M410210200","article-title":"Neuroprotective effects of phenylbutyrate in the N171-82Q transgenic mouse model of Huntington\u2019s disease","volume":"280","author":"Gardian","year":"2005","journal-title":"J Biol Chem"},{"issue":"1","key":"10.3233\/JHD-160226_ref8","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.pbb.2009.08.001","article-title":"Valproate ameliorates the survival and the motor performance in a transgenic mouse model of Huntington\u2019s disease","volume":"94","author":"Zadori","year":"2009","journal-title":"Pharmacol Biochem Behav"},{"issue":"11","key":"10.3233\/JHD-160226_ref9","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.1093\/hmg\/ddu010","article-title":"A potent and selective Sirtuin 1 inhibitor alleviates pathology in multiple animal and cell models of Huntington\u2019s disease","volume":"23","author":"Smith","year":"2014","journal-title":"Hum Mol Genet"},{"issue":"40","key":"10.3233\/JHD-160226_ref10","doi-asserted-by":"crossref","first-page":"15564","DOI":"10.1073\/pnas.0804249105","article-title":"The HDAC inhibitor 4b ameliorates the disease phenotype and transcriptional abnormalities in Huntington\u2019s disease transgenic mice","volume":"105","author":"Thomas","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"10.3233\/JHD-160226_ref11","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.nbd.2012.01.016","article-title":"Histone deacetylase (HDAC) inhibitors targeting HDAC3 and HDAC1 ameliorate polyglutamine-elicited phenotypes in model systems of Huntington\u2019s disease","volume":"46","author":"Jia","year":"2012","journal-title":"Neurobiol Dis"},{"issue":"6","key":"10.3233\/JHD-160226_ref12","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1093\/hmg\/ddr552","article-title":"Long-term memory deficits in Huntington\u2019s disease are associated with reduced CBP histone acetylase activity","volume":"21","author":"Giralt","year":"2011","journal-title":"Hum Mol Genet"},{"issue":"2","key":"10.3233\/JHD-160226_ref13","doi-asserted-by":"crossref","first-page":"e31080","DOI":"10.1371\/journal.pone.0031080","article-title":"Genetic knock-down of HDAC3 does not modify disease-related phenotypes in a mouse model of Huntington\u2019s disease","volume":"7","author":"Moumne","year":"2012","journal-title":"PLoS One"},{"issue":"6","key":"10.3233\/JHD-160226_ref14","doi-asserted-by":"crossref","first-page":"e20696","DOI":"10.1371\/journal.pone.0020696","article-title":"Hdac6 knock-out increases tubulin acetylation but does not modify disease progression in the R6\/2 mouse model of Huntington\u2019s disease","volume":"6","author":"Bobrowska","year":"2011","journal-title":"PLoS One"},{"issue":"6","key":"10.3233\/JHD-160226_ref15","doi-asserted-by":"crossref","first-page":"e5747","DOI":"10.1371\/journal.pone.0005747","article-title":"Genetic knock-down of HDAC7 does not ameliorate disease pathogenesis in the R6\/2 mouse model of Huntington\u2019s disease","volume":"4","author":"Benn","year":"2009","journal-title":"PLoS One"},{"issue":"11","key":"10.3233\/JHD-160226_ref16","doi-asserted-by":"crossref","first-page":"e1001717","DOI":"10.1371\/journal.pbio.1001717","article-title":"HDAC4 reduction: A novel therapeutic strategy to target cytoplasmic huntingtin and ameliorate neurodegeneration","volume":"11","author":"Mielcarek","year":"2013","journal-title":"PLoS Biol"},{"issue":"24","key":"10.3233\/JHD-160226_ref17","doi-asserted-by":"crossref","first-page":"9934","DOI":"10.1021\/jm4011884","article-title":"Design, synthesis, and biological evaluation of potent and selective class IIa histone deacetylase (HDAC) inhibitors as a potential therapy for Huntington\u2019s disease","volume":"56","author":"Burli","year":"2013","journal-title":"J Med Chem"},{"issue":"2","key":"10.3233\/JHD-160226_ref18","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.canlet.2009.02.019","article-title":"Development of the pan-DAC inhibitor panobinostat (LBH589): Successes and challenges","volume":"280","author":"Atadja","year":"2009","journal-title":"Cancer Lett"},{"issue":"2","key":"10.3233\/JHD-160226_ref19","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.ejca.2012.08.017","article-title":"Panobinostat activity in both bexarotene-exposed and -naive patients with refractory cutaneous T-cell lymphoma: Results of a phase II trial","volume":"49","author":"Duvic","year":"2013","journal-title":"Eur J Cancer"},{"issue":"18","key":"10.3233\/JHD-160226_ref20","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1200\/JCO.2011.38.1350","article-title":"Panobinostat in patients with relapsed\/refractory Hodgkin\u2019s lymphoma after autologous stem-cell transplantation: Results of a phase II study","volume":"30","author":"Younes","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.3233\/JHD-160226_ref21","doi-asserted-by":"crossref","first-page":"e170","DOI":"10.1038\/bcj.2013.68","article-title":"Dual epigenetic targeting with panobinostat and azacitidine in acute myeloid leukemia and high-risk myelodysplastic syndrome","volume":"4","author":"Tan","year":"2014","journal-title":"Blood Cancer J"},{"issue":"3","key":"10.3233\/JHD-160226_ref22","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s00280-013-2224-8","article-title":"A phase 2 study of intravenous panobinostat in patients with castration-resistant prostate cancer","volume":"72","author":"Rathkopf","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"issue":"10","key":"10.3233\/JHD-160226_ref23","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1097\/QAD.0000000000000678","article-title":"The histone deacetylase inhibitor panobinostat lowers biomarkers of cardiovascular risk and inflammation in HIV patients","volume":"29","author":"Hogh Kolbaek Kjaer","year":"2015","journal-title":"AIDS"},{"issue":"6","key":"10.3233\/JHD-160226_ref24","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/s40265-015-0388-8","article-title":"Panobinostat: First global approval","volume":"75","author":"Garnock-Jones","year":"2015","journal-title":"Drugs"},{"issue":"2","key":"10.3233\/JHD-160226_ref25","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/ng0297-197","article-title":"Instability of highly expanded CAG repeats in mice transgenic for the Huntington\u2019s disease mutation","volume":"15","author":"Mangiarini","year":"1997","journal-title":"Nat Genet"},{"issue":"Pt 1","key":"10.3233\/JHD-160226_ref26","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/j.1365-2818.1990.tb03019.x","article-title":"Efficient estimation of cell volume and number using the nucleator and the disector","volume":"159","author":"Moller","year":"1990","journal-title":"J Microsc"},{"issue":"3","key":"10.3233\/JHD-160226_ref27","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S0092-8674(00)81369-0","article-title":"Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice","volume":"87","author":"Mangiarini","year":"1996","journal-title":"Cell"},{"issue":"1","key":"10.3233\/JHD-160226_ref28","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/cne.10776","article-title":"Time course of early motor and neuropathological anomalies in a knock-in mouse model of Huntington\u2019s disease with 140 CAG repeats","volume":"465","author":"Menalled","year":"2003","journal-title":"J Comp Neurol"},{"issue":"4","key":"10.3233\/JHD-160226_ref29","doi-asserted-by":"crossref","first-page":"403","DOI":"10.2174\/156720506778249407","article-title":"Histone deacetylase inhibitors: A novel therapeutic approach to Huntington\u2019s disease (complex mechanism of neuronal death)","volume":"3","author":"Sadri-Vakili","year":"2006","journal-title":"Curr Alzheimer Res"},{"issue":"6","key":"10.3233\/JHD-160226_ref30","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/j.1755-5949.2010.00184.x","article-title":"Targeting histone deacetylases for the treatment of Huntington\u2019s disease","volume":"16","author":"Gray","year":"2010","journal-title":"CNS Neurosci Ther"},{"issue":"1","key":"10.3233\/JHD-160226_ref31","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.cell.2009.03.018","article-title":"Acetylation targets mutant huntingtin to autophagosomes for degradation","volume":"137","author":"Jeong","year":"2009","journal-title":"Cell"},{"issue":"9","key":"10.3233\/JHD-160226_ref32","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1517\/13543784.2013.815165","article-title":"Panobinostat in lymphoid and myeloid malignancies","volume":"22","author":"Khot","year":"2013","journal-title":"Expert Opin Investig Drugs"},{"issue":"1","key":"10.3233\/JHD-160226_ref33","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1586\/17512433.2016.1096773","article-title":"Panobinostat for the treatment of relapsed or relapsed\/refractory multiple myeloma: Pharmacology and clinical outcomes","volume":"9","author":"Richardson","year":"2016","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.3233\/JHD-160226_ref34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/00498254.2016.1184356","article-title":"Clinical pharmacokinetics of panobinostat, a novel histone deacetylase (HDAC) inhibitor: Review and perspectives","author":"Srinivas","year":"2016","journal-title":"Xenobiotica"}],"container-title":["Journal of Huntington's Disease"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/JHD-160226","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T08:57:13Z","timestamp":1777453033000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/JHD-160226"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12,15]]},"references-count":34,"journal-issue":{"issue":"4"},"URL":"https:\/\/doi.org\/10.3233\/jhd-160226","relation":{},"ISSN":["1879-6397","1879-6400"],"issn-type":[{"value":"1879-6397","type":"print"},{"value":"1879-6400","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12,15]]}}}